Treatment of infantile hemangioma: case report

Abstract

Background: Although benign in origin, infantile hemangiomas can occasionally cause lifelong deformity, functional disability, and even life-threatening consequences. As a result, therapy is favored above an active observation plan. When treating infantile hemangiomas at high risk, the first line of therapy should be systemic propranolol. While oral propranolol is generally regarded as a safe and effective medication, it is important to consider potential adverse effects. Further research and evidence-based practices are needed to improve clinical results. Case report: Here, we describe a 3-month-old child who had an infantile hemangioma and how oral propranolol significantly improved the lesion. The patient's mother takes her to the hospital when she notices a reddish mass that extends from her nasal bridge to her right cheek. After three days, the patient's red mass had lessened. The kid was monitored in the clinic for three hours following the initial increase in propranolol dosage, which was raised to 2 mg/kg/day. Every week, the patient was monitored at the clinic. The child's weight had climbed to 7 kg after 4 weeks, and she had no side effects from an increased propranolol dosage. Conclusion: A critical factor is the early diagnosis of at-risk infantile haemangiomas, which calls for pediatricians, general practitioners, and health visitors to be more alert in order to spot potentially troublesome infantile haemangiomas in the first two to three weeks of life.